In the Asia-Pacific pharmaceutical industry, there were 12 private equity deals announced in Q3 2023, worth a total value of $419.5m, according to GlobalData’s Deals Database. The $155m investment by International Finance and Quadria Capital Investment Management in Maxivision Eye Hospitals was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Asia-Pacific decreased by 91% in Q3 2023 compared with the previous quarter’s total of $4.6bn and fell by 36% as compared to Q3 2022. Related deal volume decreased by 37% in Q3 2023 versus the previous quarter and was 14% lower than in Q3 2022.
The top-ranked legal advisors supporting these private equity deals in Asia-Pacific Q3 2023 were AZB & Partners; Gilbert and Tobin; Khaitan & Co with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.